R.S. Analytics
R.S. Analytics
Send Message
R.S. Analytics
Stop FollowingR.S. Analytics
View R.S. Analytics' StockTalks BY TICKER:
-
R.S. Analytics
$VHC $AAPL going to be some fireworks tomorrow...Final ruling out and it all but slams the door shut on an Apple appeal! - View all 6 replies
-
2ng: betting against apple now is the same thing than buying apple at 700. It's simply overdone -
Tom Shaughnessy: Agreed R.S.! Wrote an article covering the order let me know what you think!
-
- View all 3 replies
-
R.S. Analytics: I currently own the stock but if I didn't I would be a buyer in the 20's. -
-
R.S. Analytics
I purchased more VHC today at $31.25. I am pretty heavily weighted in this equity but only a fool would be selling now. Obvious OPEX B.S. - View all 1 replies
-
-
R.S. Analytics
Out FIO $21.05 with decent 4 trading day gain of nearly 10%. Will buy back if it dips below $20 again. No need to get greedy here. - View all 0 replies
-
R.S. Analytics
New Article: VirnetX and Google? Will Apple Settle Or Risk Going The Distance? http://tinyurl.com/aecq768 - View all 0 replies
-
- View all 1 replies
-
vinyal: there is institutional selling going on here. dont try to catch falling knives
-
R.S. Analytics
$ARNA $AVNR $AMRN $SRPT....new article: http://tinyurl.com/bz64k3v Lots of trading opportunities coming up!!! - View all 3 replies
-
R.S. Analytics: Good call - I would wait till around $26 to position in. If they release steller 60wk data, with a low float, this could easily hit $75. -
-
R.S. Analytics
New DVAX article: http://tinyurl.com/9nk6yj7 ENJOY - It is spring-loaded for a breakout into the FDA VRBPAC panel on Nov 14-15 & Feb PDUFA - View all 0 replies
-
R.S. Analytics
DVAX...November 14 FDA Advisory Panel on Hepsilav. Good time to jump on board right now for the run-up. - View all 1 replies
-
-
R.S. Analytics
Sarepta!!!! This is an incredible advancement for the treatment of DMD! God Bless the researchers that develop these medicines! - View all 0 replies
-
R.S. Analytics
QCOR - Wow...just wow, sorry longs. Hopefully other insurers won't follow Aetna's lead. Should be interesting tomorrow. - View all 1 replies
-
-
- View all 4 replies
-
R.S. Analytics: If the 48 week data is positive for eteplirsen I think SRPT will easily hit $20+. Small float, large short interest, accelerated approval. -
-
R.S. Analytics
Sarepta is running again. I really like this company and am hopefully optimistic for all the sufferers out there with DMD. - View all 0 replies
